the role of ykl-40 and dipeptidyl peptidase-4 in asthma: a narrative review

Background: asthma is a complex and heterogeneous disease characterized by chronic inflammation, airway remodeling, and variable clinical manifestations. despite advances in asthma management, there is a need for novel biomarkers to improve diagnosis, predict disease severity, and monitor treatment responses.objective: to review the current evidence on the role of ykl-40 and dipeptidyl peptidase-4 (dpp-4) in asthma, including their potential as biomarkers for disease severity, treatment responses, and genetic predisposition.methods: a comprehensive literature search was conducted to identify studies investigating the relationship between ykl-40, dpp-4, and asthma. relevant articles were selected based on their relevance to the topic and study design.results: the review highlights the association of ykl-40 with airway remodeling, inflammation, and disease severity in asthma. elevated ykl-40 levels have been linked to poor prognosis, increased exacerbations, and reduced lung function. genetic variations in the chi3l1 gene, which encodes ykl-40, have been associated with asthma susceptibility and severity. dpp-4 has been implicated in the regulation of inflammation and immune responses in asthma, with studies suggesting its potential role in modulating airway inflammation and remodeling.conclusion: ykl-40 and dpp-4 are promising biomarkers for asthma, with potential applications in disease diagnosis, severity assessment, and treatment monitoring. further research is needed to fully elucidate their roles in asthma pathophysiology and to explore their clinical utility in asthma management.